… We are entering a new era for clinical oral anticoagulation use, and although vitamin K … ,
including dabigatran, apixaban and rivaroxaban, has created new avenues for the prevention or …

… Rivaroxaban and apixaban were approved … new oral anticoagulants targeting factor Xa.
They selectively bind to the active site of free and clot-bound factor Xa, which leads to inhibition …

… Likewise, in the ADOPT study, extended-duration thromboprophylaxis with apixaban failed
… , Inc) is a new, long-acting, oral, selective factor Xa (FXa) inhibitor that has demonstrated …

… 0.27) anti-Xa activity between rivaroxaban-treated and apixaban-treated … oral factor Xa
inhibitor therapy (range 7–911 days reported by Ikeda vs. 5 days of single oral factor Xa inhibitor …

… of Factor Xa inhibitors (FXaIs), currently four drugs: rivaroxaban (Xarelto), apixaban (Eliquis), …
In patients who had received apixaban, the median anti-factor Xa activity decreased from …

… Oral factor Xa inhibitors (FXaI) can be administered in fixed doses without the need for …
levels may be useful in guiding decisions for reversal of anticoagulation in emergent settings, …

… However, we found that the validated STA-Liquid Anti-Xa assay using calibrator kits for
apixaban and rivaroxaban and LC–MS/MS data for edoxaban had similar calibration lines for the …

… of oral FXa inhibitors like rivaroxaban, apixaban and … , some new anticoagulants targeting
thrombin or factor Xa (… Out of them, the first orally active direct thrombin inhibitors (DTIs), ximela…

… role of anti-Xa levels in managing patients with an emergent … of rivaroxaban and apixaban
before emergent procedures or … apixaban and rivaroxaban reversal utilizes factor 8 inhibitor …

… The finding that rivaroxaban and apixaban have a role in fibrinolysis may suggest new
clinical applications, such as for post‐thrombotic syndrome (PTS) 45., 46.. A potential basis for …